文献速递血管炎

吗替麦考酚酯作为ANCA相关性血管炎缓解诱导治疗的疗效:一项Meta分析

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
PubMed 文献 · RMD Open · 2020-01-01

该系统评价与Meta分析纳入4项随机对照试验共300例ANCA相关性血管炎患者,比较吗替麦考酚酯(MMF)与环磷酰胺(CYC)的缓解诱导疗效。结果显示两组在6个月缓解率、6个月ANCA转阴率、长期复发率及死亡、感染、白细胞减少发生率上均无显著差异。MMF可能作为非危及生命AAV的替代缓解诱导治疗。

要点

  • MMF与CYC在AAV缓解诱导中的疗效无显著差异。
  • 6个月缓解率、ANCA转阴率及长期复发率两组相似。
  • MMF或可作为非危及生命AAV的替代缓解诱导治疗。

核心结论

  • 在AAV患者中,MMF与CYC的缓解诱导治疗疗效无差异。
  • MMF可能作为非危及生命AAV患者的替代缓解诱导治疗。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane Library和Google Scholar比较MMF与CYC疗效的随机对照试验。
  • 共纳入4项RCT、300例AAV患者,采用Mantel-Haenszel随机效应模型比较相对危险度(RR)。

主要发现

  • 6个月缓解率两组相似(RR 1.09,95%CI 0.86至1.38,p=0.48)。
  • 6个月ANCA转阴率两组相似(RR 1.31,95%CI 0.91至1.90,p=0.15)。
  • 长期复发率两组相似(RR 1.36,95%CI 0.80至2.31,p=0.26)。
  • 死亡、感染和白细胞减少发生率两组亦相似(RR 1.05,95%CI 0.40至2.74,p=0.93;RR 1.26,95%CI 0.79至2.01,p=0.33;RR 0.45,95%CI 0.16至1.32,p=0.15)。

关键数值与推荐

  • 6个月缓解率:RR 1.09,95%CI 0.86至1.38,p=0.48。
  • 6个月ANCA转阴率:RR 1.31,95%CI 0.91至1.90,p=0.15。
  • 长期复发率:RR 1.36,95%CI 0.80至2.31,p=0.26。
  • 死亡:RR 1.05,95%CI 0.40至2.74,p=0.93;感染:RR 1.26,95%CI 0.79至2.01,p=0.33;白细胞减少:RR 0.45,95%CI 0.16至1.32,p=0.15。

临床怎么用

  • 对于非危及生命的AAV患者,可考虑MMF作为CYC的替代缓解诱导治疗。
  • 临床决策时需结合患者病情严重程度及个体化评估选择MMF或CYC。

局限性

  • 仅纳入4项RCT共300例患者,样本量有限。
  • 原文未报告纳入研究的偏倚风险、异质性及具体疾病亚型分布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A few studies on antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treatments have shown the therapeutic efficacy of mycophenolate mofetil (MMF). However, the therapeutic efficacy of MMF compared with that of cyclophosphamide (CYC) in patients with AAV has not been established. We conducted a systematic review and meta-analysis to assess the efficacy of MMF as a remission induction therapy in patients with AAV comparing it with the efficacy of CYC. METHODS: We searched randomised controlled trials (RCTs) comparing the efficacy of MMF with that of CYC in patients with AAV on three different websites: PubMed, Cochrane Library and Google Scholar. We compared the difference in the relative risk (RR) of each outcome based on a Mantel-Haenszel random-effects model. RESULTS: We analysed data from four RCTs with 300 patients for the study. The 6-month remission rate (RR 1.09, 95% CI 0.86 to 1.38, p=0.48), the 6-month ANCA negativity (RR 1.31, 95% CI 0.91 to 1.90, p=0.15) and the long-term relapse rate (RR 1.36, 95% CI 0.80 to 2.31, p=0.26) were all similar between the two treatments. The rates of death, infection and leucopenia were also similar between the two groups (RR 1.05, 95% CI 0.40 to 2.74, p=0.93; RR 1.26, 95% CI 0.79 to 2.01, p=0.33; RR 0.45, 95% CI 0.16 to 1.32, p=0.15, respectively). CONCLUSIONS: We found no difference between the therapeutic efficacy of MMF and that of CYC in patients with AAV. MMF may be an alternative remission induction therapy in patients with non-life-threatening AAV.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kuzuya K, Morita T, Kumanogoh A, et al. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis. RMD Open. 2020. PMID: 32371435. doi:10.1136/rmdopen-2020-001195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。